A Case of Refractory Hidradenitis Suppurativa Successfully Treated With Upadacitinib

Hidradenitis suppurativa (HS) is a chronic, disabling inflammatory disease with a high unmet medical need, characterized by persistent, painful skin nodules, abscesses, and draining tunnels. Research on HS is rapidly evolving, with a variety of agents with different mechanisms of action being developed. As several Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathways are involved in the pathogenesis of HS, JAK inhibitors represent a promising therapeutic target. Herein, we present a case of severe hidradenitis suppurativa treated with upadacitinib following the failure of adalimumab and secukinumab.